GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Prior treatment

• Previously treated with any genetically engineered modified T cell therapy (TCR-T/CAR-T) or other CGT
• Uncontrolled or active infection at screening, prior to APH, 72 hours prior to lymphodepletion or 5 days prior to JWATM214 infusion
• ≥G2 hemorrhage within 30 days prior to screening, or in need of long-term anticoagulants
• Active digestive ulcer or gastrointestinal bleeding within 3 months prior to screening
• Previously allergic or intolerable to JWATM214 or its components

Other illness

• Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
• Systematic autoimmune disorders requiring long-term systematic immunosuppression
• Active HCV, HIV, or syphilis
• History of organ transplant
• With severe cardiovascular disease
• History or presence of clinically-relevant CNS disorders

Other

• Cholangiocarcinoma or histological-mixed hepatocellular cholangiocarcinoma
• Active brain metastasis
• Primary lesion or infused lesions with the longest diameter ≥15cm, or other potential risk which might not be appropriate for further study treatment judged by the investigator
• Current presence of hepatic encephalopathy
• Pregnant or lactating women
• Not satisfying wash-out period for APH
• Unable or unwilling to comply with the study protocol, judged by the investigator
• Other situations implying that the subject might not be appropriate to participate in the study

• 18-75 years-old, male or female
• Voluntarily willing to participate in the study and sign the written informed consent form
• Life expectation ≥12 weeks
• Eastern Cooperative Oncology Group (ECOG) performance status scale ≤1
• Histologically-confirmed hepatocellular carcinoma (HCC)
• No benefits from curative surgery or other local therapies are expected at screening, judged by investigators
• Radiologically-confirmed progression disease after at least one prior line of systematic treatment and limited benefits from current guideline or consensus for hepatocellular carcinoma are expected at screening, judged by investigators
• Fresh samples or FFPE, immunohistochemistry (IHC)-stained GPC-3 positive with intensity ++ or +++
• Per RECIST v1.1, at least one measurable lesion
• Manageable lung metastasis
• Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
• No active HBV infections
• Adequate organ functions
• Adequate venous access for APH
• Non-hematological AEs induced by previous treatment must have recovered to CTCAE ≤1, except for alopecia and peripheral neuropathy
• Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1year post infusion, and sperm donation is prohibited during the study
• Women of childbearing potential must have negative serum β-hCG test result at screening and 48 hours prior to lymphodepletion